Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Rhumbline Advisers

Rhumbline Advisers decreased its holdings in Exact Sciences Co. (NASDAQ:EXAS) by 2.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 217,428 shares of the medical research company’s stock after selling 5,997 shares during the quarter. Rhumbline Advisers owned 0.12% of Exact Sciences worth $12,217,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Chicago Partners Investment Group LLC boosted its holdings in shares of Exact Sciences by 1.7% in the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock worth $651,000 after buying an additional 158 shares during the period. Perigon Wealth Management LLC lifted its position in shares of Exact Sciences by 3.2% in the 4th quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock valued at $474,000 after acquiring an additional 264 shares in the last quarter. Huntington National Bank boosted its stake in Exact Sciences by 838.1% in the 3rd quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after purchasing an additional 352 shares during the period. CIBC Asset Management Inc grew its position in Exact Sciences by 6.1% during the 3rd quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company’s stock worth $442,000 after purchasing an additional 371 shares in the last quarter. Finally, Advisors Asset Management Inc. raised its stake in Exact Sciences by 1.4% during the 3rd quarter. Advisors Asset Management Inc. now owns 28,650 shares of the medical research company’s stock valued at $1,952,000 after purchasing an additional 402 shares during the period. Institutional investors own 88.82% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on EXAS shares. TD Cowen raised their target price on Exact Sciences from $82.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Craig Hallum decreased their price objective on Exact Sciences from $82.00 to $65.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Stifel Nicolaus dropped their target price on Exact Sciences from $82.00 to $67.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Piper Sandler decreased their price target on shares of Exact Sciences from $85.00 to $75.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Finally, Benchmark reaffirmed a “buy” rating and set a $65.00 price objective on shares of Exact Sciences in a research report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $72.06.

Exact Sciences Trading Down 0.5 %

Shares of NASDAQ:EXAS opened at $49.26 on Monday. Exact Sciences Co. has a 1 year low of $40.62 and a 1 year high of $79.62. The firm has a fifty day moving average price of $54.91 and a 200 day moving average price of $60.04. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. The stock has a market capitalization of $9.15 billion, a PE ratio of -8.84 and a beta of 1.24.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Analysts expect that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.